Pancreatic Cancer Program
Clinical Trials
Learn about clinical trials, courtesy of the Pancreatic Cancer Action Network
One of the unique benefits of being a University of Michigan patient is access to the latest and most promising therapies for cancer. Our doctors are working hard to find cures, but they can't do it alone. Patients play a vital role by participating in research studies -- also known as clinical trials.
Featured Trials
For those with borderline operable pancreatic cancer
Title: UMCC 2011.007 A Phase II Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine with Concurrent IMRT in Patients with
Borderline Resectable Pancreatic Cancer
Purpose: This research study will examine a sequence of treatments including pre-operative chemotherapy, radiation and finally surgery for borderline resectable pancreatic cancer.
Study Description: To improve the results of current standard treatments for pancreatic cancer through development of new medications. This research treatment will evaluate the combination of two chemotherapy agents, FOLFIRINOX and gemcitabine, combined with radiation therapy. FOLFIRINOX is actually a combination of four chemotherapy agents, 5-fluorouracil, leucovorin, irinotecan and oxaliplatin. The researchers have already done studies FOLFOX chemotherapy (a combination of leucovorin, 5-fluorouracil, and oxaliplatin), as well as gemcitabine and oxaliplatin combined with radiation therapy. They want to build on the information they have from this previous research. They will use this study to determine how well people do who are treated with FOLFIRINOX, gemcitabine and radiation therapy prior to having surgery for their pancreatic cancer. The researchers will also gather more information about what type of side effects occur with this treatment.
Read about eligibility or get contact information.
Purpose: This research study will examine a sequence of treatments including pre-operative chemotherapy, radiation and finally surgery for borderline resectable pancreatic cancer.
Study Description: To improve the results of current standard treatments for pancreatic cancer through development of new medications. This research treatment will evaluate the combination of two chemotherapy agents, FOLFIRINOX and gemcitabine, combined with radiation therapy. FOLFIRINOX is actually a combination of four chemotherapy agents, 5-fluorouracil, leucovorin, irinotecan and oxaliplatin. The researchers have already done studies FOLFOX chemotherapy (a combination of leucovorin, 5-fluorouracil, and oxaliplatin), as well as gemcitabine and oxaliplatin combined with radiation therapy. They want to build on the information they have from this previous research. They will use this study to determine how well people do who are treated with FOLFIRINOX, gemcitabine and radiation therapy prior to having surgery for their pancreatic cancer. The researchers will also gather more information about what type of side effects occur with this treatment.
Read about eligibility or get contact information.
For those with advanced pancreatic and biliary cancers
Title: UMCC 2011-036 Phase II Trial for Advanced pancreatic and biliary cancers
Purpose: To evaluate the combination of 3 chemotherapy drugs, gemcitabine, infusional 5-fluorouracil (5FU) and cisplatin for patients with metastatic pancreatic and biliary cancers.
Study Description: Researchers will use this study to determine how well people do who are treated with gemcitabine, infusional 5-fluorouracil (5-FU) and cisplatin. The researchers will also gather more information about what type of side effects occur with this treatment. Patients who have been treated previously with a single drug of gemcitabine and /or 5FU may be eligible for this trial. Those patients who have been treated previously with cisplatin are not eligible.
Read about eligibility or get contact information.
Purpose: To evaluate the combination of 3 chemotherapy drugs, gemcitabine, infusional 5-fluorouracil (5FU) and cisplatin for patients with metastatic pancreatic and biliary cancers.
Study Description: Researchers will use this study to determine how well people do who are treated with gemcitabine, infusional 5-fluorouracil (5-FU) and cisplatin. The researchers will also gather more information about what type of side effects occur with this treatment. Patients who have been treated previously with a single drug of gemcitabine and /or 5FU may be eligible for this trial. Those patients who have been treated previously with cisplatin are not eligible.
Read about eligibility or get contact information.
Questions?
If you would like to speak- to someone about this trial -- or other trials available at the University of Michigan Health System -- please contact the Cancer AnswerLine™ at 800-865-1125.
Last update 01/2013
Adjust Text Size